SCHEDULE: Coastlands Capital Reduces Stake in Eloxx Pharmaceuticals

Coastlands Capital LP and its affiliates have filed an exit statement after reducing their beneficial ownership in Eloxx Pharmaceuticals to 4.99%.

Summary

• Coastlands Capital LP and associated entities filed an Amendment No. 1 to Schedule 13G regarding their holdings in Eloxx Pharmaceuticals, Inc.
• The reporting group now beneficially owns 266,539 shares of common stock, representing 4.99% of the company.
• The ownership consists of shares issuable upon the exercise of pre-funded warrants.
• This filing serves as an exit filing, as the reporting persons no longer beneficially own more than 5% of the issuer's securities.
• The calculation is based on 5,074,935 shares of common stock outstanding as of May 27, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative to neutral; while the investor remains a significant holder, the reduction below the 5% threshold and the filing of an 'exit' statement suggests a cooling of interest or a strategic rebalancing.

Positives

• Coastlands Capital maintains a significant investment in the company, holding just under the 5% reporting threshold.
• The investment is structured through pre-funded warrants, providing flexibility in capital commitment.

Negatives

• A major institutional investor has reduced its stake below the 5% threshold, which may indicate a reduction in long-term conviction.
• The exit filing means the investor will no longer be required to provide regular public updates on their ownership unless they cross the 5% threshold again.

Risks

• Potential for further selling by Coastlands Capital now that they are below the 5% reporting requirement.
• Market perception of a major shareholder reducing their position can lead to downward pressure on the stock price.

Future Outlook

The filing does not provide specific forward-looking guidance for the company's operations, but indicates the reporting persons have moved to a position where they are no longer required to report ownership changes under Schedule 13G.

Management Comments

• The reporting persons stated that the securities were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, institutional investors often adjust positions around clinical milestones or capital raises. A move to exactly 4.99% is a common strategic threshold used by funds to avoid the regulatory burdens and 'insider' classifications associated with owning 5% or more of a company.

Comparison to Industry Standards

• The 4.99% ownership cap is a standard industry practice for hedge funds and investment advisers to maintain liquidity while avoiding Section 16 reporting requirements.
• Compared to larger biotech peers, Eloxx Pharmaceuticals has a relatively small share count (approx. 5 million shares), making individual institutional moves highly impactful on total ownership percentages.

Stakeholder Impact

• Shareholders may experience increased price volatility if the market interprets this reduction as a lack of confidence from a major institutional backer.

Next Steps

• Monitor for any subsequent Form 4 filings if the reporting persons are deemed insiders or if they further liquidate their position.
• Watch for company news that may have prompted the institutional stake reduction.

Key Dates

Recommendation

The reduction in stake to just below the reporting threshold is a cautious signal, but since the investor still holds nearly 5% through warrants, it does not necessarily indicate a total exit. Investors should hold and monitor for further institutional selling or company-specific catalysts.

Keywords

Eloxx Pharmaceuticals, Coastlands Capital, Schedule 13G, Beneficial Ownership, Pre-funded Warrants, Institutional Investment, Biotech, Matthew D. Perry